You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 23, 2024

Amgen Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Drugs and US Patents for Amgen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
Amgen Inc LUMAKRAS sotorasib TABLET;ORAL 214665-001 May 28, 2021 RX Yes No 11,426,404 ⤷  Sign Up ⤷  Sign Up
Amgen Inc LUMAKRAS sotorasib TABLET;ORAL 214665-001 May 28, 2021 RX Yes No 11,827,635 ⤷  Sign Up Y Y ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 AB RX Yes Yes 7,427,638 ⤷  Sign Up Y Y ⤷  Sign Up
Amgen Inc CORLANOR ivabradine SOLUTION;ORAL 209964-001 Apr 22, 2019 RX Yes Yes 7,361,650 ⤷  Sign Up Y Y ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 AB RX Yes No 10,092,541 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Amgen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 8,455,536 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 9,724,330 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 7,659,302 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 7,893,101 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 8,802,717 ⤷  Sign Up
Amgen Inc OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 7,893,101 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for AMGEN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 30 mg, 60 mg and 90mg ➤ Subscribe 2008-03-10
➤ Subscribe Tablets 10 mg, 20 mg and30 mg ➤ Subscribe 2018-03-22

Supplementary Protection Certificates for Amgen Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2962690 2019C/008 Belgium ⤷  Sign Up DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION
2962690 122019000070 Germany ⤷  Sign Up PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 20150115
2962690 1990037-2 Sweden ⤷  Sign Up PRODUCT NAME: APREMILAST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/981 20150116
2962690 C20190029 00295 Estonia ⤷  Sign Up PRODUCT NAME: APREMILAST;REG NO/DATE: EU/1/14/981 16.01.2015
2962690 C02962690/01 Switzerland ⤷  Sign Up VERTRETERLOESCHUNG
2962690 CA 2019 00033 Denmark ⤷  Sign Up PRODUCT NAME: APREMILAST ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/981 20150116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.